An accurate estimate of future GFR after nephrectomy would help to guide operative strategy and use of adjuvant or neoadjuvant therapies, according to a recent editorial.
Adjuvant chemotherapy prolongs survival among patients with negative surgical margins regardless of number of positive lymph nodes.
Findings may inform surveillance strategies and improve treatment outcomes.
Approximately one-quarter of patients aged 80 years or older with upper tract urothelial carcinoma are managed expectantly, data show.
In a study, distant metastasis emerged as the best candidate to be a surrogate end point for survival among patients receiving surgical treatment for UTUC.
Segmental ureterectomy is increasingly adopted for high-risk upper tract urothelial carcinoma.
A recent study characterized disease recurrence patterns and predictive risk factors for recurrence in patients who underwent radical nephroureterectomy for low-grade upper tract urothelial carcinoma.
In this small study, even patients with high-risk tumors appeared to benefit from nephron-sparing surgery.
Neoadjuvant chemotherapy prior to radical nephroureterectomy for upper tract urothelial carcinoma may improve pathologic outcomes regardless of age, new data suggest.
If validated, the EpiCheck® assay may identify more patients who can safely delay or avoid nephroureterectomy.